Kite Pharmaceuticals Submits Application for New Lymphoma Therapy
How many patients would this help?
If one looks at how many people suffer from non-Hodgkin's lymphoma, or NHL, every year, only in Europe, they will find approximately 93,000 people. This type of blood cancer also has aggressive subtypes, such as DLBCL, which grows quickly.
Many patients experience complete remission after their first treatment, but some will relapse or don't even respond to the preliminary treatment. For these patients, unfortunately, the outcomes have shown to be negative.
Kite Pharmaceuticals has revealed their estimate of about 7,800 patients being aided by their CAR-T therapy, just in the EU 5.
